𝔖 Bobbio Scriptorium
✦   LIBER   ✦

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Scribed by Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Hielscher, Jörg; Scholz, Michael; Müller, Sebastian; Link, Hartmut; Niederle, Norbert; Rost, Andreas; Höffkes, Heinz-Gert; Moehler, Markus; Lindig, Reinhard U; Modest, Dominik P; Rossius, Lisa; Kirchner, Thomas; Jung, Andreas; Stintzing, Sebastian

Book ID
125844312
Publisher
Lancet Publishing Group
Year
2014
Tongue
English
Weight
289 KB
Volume
15
Category
Article
ISSN
1470-2045

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FOLFIRI plus cetuximab versus FOLFIRI pl
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow